É mesmo, olhando o fecho anterior a abertura de hoje! :o
---------------------------------------------------------------------------------------------------
6:21AM Noven Pharma announces results of Daytrana advisory committee meeting late Friday Dec. 2nd afternnoon (NOVN) 11.17 :Late Friday Dec. 2 the co announced the results of the Psychopharmacologic Drugs Advisory Committee meeting held earlier relating to Daytrana. Daytrana, licensed globally to Shire plc (SHPGF), is an investigational transdermal patch designed for once-daily use to treat attention deficit hyperactivity disorder in children aged 6 to 12 years. An amended New Drug Application for Daytrana is currently pending at the FDA. The Committee voted unanimously in favor of the efficacy of the product. The Committee voted unanimously in favor of the safety of the product, but recommended that the FDA require post-marketing surveillance and/or studies related to the product. The Advisory Committee also recommended to the FDA that consideration of oral ADHD products be given prior to use of the product, but by a vote of eleven to one rejected a proposal to limit use of the product to patients who cannot use oral methylphenidate products.
Realmente o fecho confirmou a boa abertura e apesar de não já algum tempo a mercado accionista, acho que existe aqui uma boa oportunidade. ;) Apesar de neste momento estarmos numa zona de alguma resistência, e caso haja uma quebra acho que possivelmente a NOVN poderá atingir os $18... ::)
A ver vamos.